Drug intelligence / Profile preview

ibi310 + sintilimab + bevacizumab

Development stage: Unknown
Lead developer: Innovent Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI310 + sintilimab + bevacizumab is a triple biologic combination regimen investigated for the treatment of hepatocellular carcinoma (HCC). The regimen consists of IBI310, an anti-CTLA-4 monoclonal antibody; sintilimab, an anti-PD-1 monoclonal antibody; and bevacizumab, an anti-VEGF monoclonal antibody. This combination therapy utilizes dual immune checkpoint blockade (targeting CTLA-4 and PD-1) alongside anti-angiogenic therapy (targeting VEGF) to enhance antitumor immune responses and inhibit tumor vascularization. Developed by Innovent Biologics, the combination is being evaluated in the Phase Ib/II "Prophet" study for peri-operative treatment of resectable HCC and has been explored in various clinical settings for advanced liver cancer.

Brand names: Byvasda
Other names: IBI310 plus sintilimab plus bevacizumabIBI-310 plus sintilimab plus bevacizumabIBI 310 plus sintilimab plus bevacizumab

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on ibi310 + sintilimab + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibi310 + sintilimab + bevacizumab.

Explore the full profile